Search
for
Sort by
Research 241–270 of 1000+
- 708 Promotion of hair growth in alopecia areata by topical treatment of HDAC inhibitors
- 688 Efficacy of topical Vorinostat in the reversal of alopecia areata
- 496 Identification of differentially expressed miRNAs in alopecia areata that target immune-regulatory pathways
- Janus kinase (JAK)
- Janus Kinase Inhibitors against Other Biological Treatments in Alopecia Areata
- Alopecia universalis following interferon alfa-2b and ribavirin treatment for hepatitis C.
- Current and future pharmacotherapy for alopecia areata
- Bullous Lesions at Polyethylene Glycol Interferon-alpha-2a Inoculation Site in a Hepatitis C Virus-infected Subject
- Clinical Characteristics and Factors Associated with Hair Loss Severity in Chronic Hepatitis B Patients Receiving Pegylated Interferon-Alpha: A Retrospective Cohort Study
- JAK Family Expression and Therapeutic Implications in Primary Cicatricial Alopecias
- A randomized controlled clinical trial of recombinant interferon α‐2b in the treatment of acute post‐transfusion hepatitis C: A preliminary report
- Pegylated-interferon-α<sub>2a</sub>in clinical practice: how to manage patients suffering from side effects
- Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report
- LB943 Tofacitinib treatment of inflammatory skin conditions in patients with Down Syndrome
- Inflammatory priming enhances mesenchymal stromal cell secretome potential as a clinical product for regenerative medicine approaches through secreted factors and EV-miRNAs: the example of joint disease
- Concomitant Vitiligo and Psoriasis in a Patient Treated with Interferon Alfa‐2a for Chronic Hepatitis B Infection
- Multiple sclerosis: Side effects of interferon beta therapy and their management
- Predictive factors for adverse dermatological events during pegylated/interferon alpha and ribavirin treatment for hepatitis C
- ROS-responsive hydrogel-delivered miR-665 targets STAT3 to alleviate inflammation and promote hair follicle regeneration in alopecia areata
- ROS-responsive hydrogel-delivered miR-665 targets STAT3 to alleviate inflammation and promote hair follicle regeneration in alopecia areata
- Lymphocytes, neuropeptides, and genes involved in alopecia areata
- Trained Immunity and Local Innate Immune Memory in the Lung
- Vitiligo and alopecia areata: apples and oranges?
- Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management
- Analysing the dynamics of a model for alopecia areata as an autoimmune disorder of hair follicle cycling
- Alopecia areata: from pathophysiology to therapeutic innovation
- Evaluation of Serum Toll-Like Receptor 4, Interferon Gamma, and Interleukin-17 Levels in Iraqi Patients with Alopecia Areata
- 1315 An Integrated model of alopecia areata biomarkers highlights both Th1/Th2 upregulation, with stronger correlations between Th2 activation and disease severity
- Hair Follicle Mesenchyme-Associated PD-L1 Regulates T-Cell Activation Induced Apoptosis: A Potential Mechanism of Immune Privilege
- Betulinic acid exerts anti‐hepatitis C virus activity via the suppression of NF‐κB‐ and MAPK‐ERK1/2‐mediated COX‐2 expression